Utama › Kanser Prostat Rintangan Kastra
Kajian klinikal Kanser Prostat Rintangan Kastra sedang mengambil peserta di AS
18 kajian untuk Kanser Prostat Rintangan Kastra sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Los Angeles, CA8 kajian
- New York City, NY7 kajian
- Seattle, WA6 kajian
- Houston, TX6 kajian
- Boston, MA5 kajian
- Pittsburgh, PA4 kajian
- Queens, NY4 kajian
- Philadelphia, PA4 kajian
- Mountain View, CA3 kajian
- Dallas, TX3 kajian
- Nashville, TN3 kajian
- Baltimore, MD3 kajian
- Cincinnati, OH3 kajian
- San Francisco, CA3 kajian
- Minneapolis, MN3 kajian
- St. Louis, MO3 kajian
- Myrtle Beach, SC3 kajian
- Grand Rapids, MI3 kajian
- San Diego, CA3 kajian
- Arlington, VA3 kajian
- Metairie, LA3 kajian
Mengikut negeri
- California11 kajian
- Connecticut3 kajian
- Florida5 kajian
- Illinois3 kajian
- Louisiana3 kajian
- Maryland3 kajian
- Massachusetts5 kajian
- Michigan7 kajian
- Minnesota4 kajian
- Missouri3 kajian
- Nebraska3 kajian
- New Jersey4 kajian
- New York8 kajian
- North Carolina4 kajian
- Ohio4 kajian
- Oregon3 kajian
- Pennsylvania5 kajian
- South Carolina4 kajian
- Tennessee5 kajian
- Texas7 kajian
- Virginia4 kajian
- Washington6 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 25 Sep 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 24 Sep 2026 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 10 Sep 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Mengambil pesertaFasa 1
Umur 18 hingga 100 · Lelaki · Dikemas kini 13 Ogo 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 10 Ogo 2026 · NCT06067841A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 115 · Lelaki · Dikemas kini 16 Jul 2026 · NCT07677267A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 115 · Lelaki · Dikemas kini 16 Jul 2026 · NCT07677254A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Lelaki · Dikemas kini 29 Mei 2026 · NCT0725840764Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Lelaki · Dikemas kini 6 Mei 2026 · NCT04868604Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Mengambil pesertaFasa 2
Umur 18 ke atas · Lelaki · Dikemas kini 13 Apr 2026 · NCT04337580Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Lelaki · Dikemas kini 13 Apr 2026 · NCT06190899Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 21 Nov 2025 · NCT0574362118F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Mengambil pesertaFasa 4
Umur 18 ke atas · Lelaki · Dikemas kini 27 Nov 2024 · NCT06706921Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.